-
Tytuł:
-
[Provision of alemtuzumab safety is one of the main components of pharmacovigilance].
-
Autorzy:
-
Khachanova NV; Pirogov Russian National Research Medical University, Moscow, Russia.
Bakhtiyarova KZ; Bashkir State Medical University, Ufa, Russia.
Boyko AN; Pirogov Russian National Research Medical University, Moscow, Russia.
Vlasov YV; Samara State Medical University, Samara, Russia.
Davydovskaia MV; Pirogov Russian National Research Medical University, Moscow, Russia; Scientific and Practical Center for Clinical Research and Medical Technologies Assessment of the Department of Health of the City of Moscow, Moscow, Russia.
Evdoshenko EP; City Center of Multiple Sclerosis and Other Autoimmune Diseases City Clinical Hospital #31, St-Petersburg, Russia; Pavlov Saint-Petersburg State Medical University, St-Petersburg, Russia.
Zakharova MN; Research Center of Neurology, Moscow, Russia.
Malkova NA; Novosibirsk State Medical University, Novosibirsk, Russia.
Sivertseva SA; Tyumen Regional Multiple Sclerosis Center, Tyumen, Russia.
Spirin NN; Yaroslavl State Medical University, Yaroslavl, Russia.
Stolyarov ID; Bechtereva Institute of Human Brain, St-Petersburg, Russia.
Schmidt TE; Sechenov First Moscow State Medical University, Moscow, Russia.
Khabirov FA; Kazan State Medical Academy, Kazan, Russia.
-
Transliterated Title:
-
Obespechenie bezopasnosti terapii alemtuzumabom - odna iz glavnykh sostavliaiushchikh farmakonadzora.
-
Źródło:
-
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova [Zh Nevrol Psikhiatr Im S S Korsakova] 2018; Vol. 118 (8. Vyp. 2), pp. 82-87.
-
Typ publikacji:
-
Journal Article
-
Język:
-
Russian
-
Imprint Name(s):
-
Publication: <1995->: Moskva : Media Sfera
Original Publication: Moskva : "Meditsina",
-
MeSH Terms:
-
Meningoencephalitis*
Multiple Sclerosis*
Alemtuzumab ; Humans ; Pharmacovigilance
-
Contributed Indexing:
-
Keywords: alemtuzumab; listeriosis; multiple sclerosis
Local Abstract: [Publisher, Russian] Современная терапия препаратами, изменяющими течение рассеянного склероза, характеризуется рисками опасных инфекционных осложнений. В последние 5 лет появились сообщения о развитии тяжелой, иногда летальной, листериозной инфекции у пациентов, получавших терапию алемтузумабом. Представлен клинический случай летального листериозного менингоэнцефалита, возникшего через 7 сут после завершения первого цикла терапии алемтузумабом. В январе 2018 г. прошло заседание Экспертного совета, на котором были пересмотрены и обновлены клинические рекомендации, опубликованные в 2017 г.
-
Substance Nomenclature:
-
3A189DH42V (Alemtuzumab)
-
Entry Date(s):
-
Date Created: 20180831 Date Completed: 20190531 Latest Revision: 20190531
-
Update Code:
-
20240105
-
DOI:
-
10.17116/jnevro201811808282
-
PMID:
-
30160673
-
Modern multiple sclerosis therapy with disease-modifying drugs is characterized by the risks of dangerous infectious complications. In the last 5 years, there have been several reports of severe, sometimes lethal, listeriosis infection in patients treated with alemtuzumab. This article presents a clinical case of lethal listeriosis meningoencephalitis, which developed within 7 days after the completion of the first cycle of alemtuzumab therapy. In January 2018, a meeting of the expert Council was held, at which the clinical recommendations published in 2017 were revised and updated.
